Abstract: Disclosed are a caspofungin analog, and a preparation method and applications thereof. The caspofungin analog has a structure as represented in Formula 3.

Abstract: Disclosed is a high purity cyclopeptide compound, the chemical structure of which is represented by formula (I). R represents H or a cation capable of forming a pharmaceutically acceptable salt, the purity being greater than or equal to 99.0%. Further disclosed are preparation method and use of the high purity cyclopeptide compound.

Abstract: Disclosed are a caspofungin analog and applications thereof. The caspofungin analog is a compound having a structure as indicated in Formula (4), or pharmaceutically acceptable salts thereof. R1 can be chosen from hydroxyl, benzyloxy, phenoxy, substituted phenoxy, or substituted benzyloxy. R2, R3, R4, R5 can be chosen from hydrogen, C1-C6 alkyl, C1-C6 alkoxy, hydroxyl, benzyloxyphenyl, substituted benzyloxyphenyl, nitro, fluorine, chlorine, bromine, or iodine. Also disclosed are a preparation method for and applications of the compound.

Abstract: Disclosed is a hydrate of a compound as shown in Formula I. In formula I, R represents H or a cation capable of forming a pharmaceutically acceptable salt. The mass percentage of water in the hydrate is more than 8%. The hydrate has good stability. Moreover, disclosed are a preparation method and a use thereof.

Abstract: Provided are a crystal form B of a compound having the structure as represented by formula I, and preparation method and use thereof. The X-ray powder diffraction (XRPD) chart of the crystal form B has characteristic peaks at the following diffraction angles: 2.9±0.2°, 6.5±0.2°, 12.6±0.2°, 13.1±0.2° and 20.6±0.2°.

Abstract: Provided are a crystal form A of a compound having the structure as represented by formula I, and preparation method and use thereof. The X-ray powder diffraction (XRPD) chart of the crystal form A has characteristic peaks at the following diffraction angles: 2.9±0.2°, 13.6±0.2°, 17.3±0.2° and 18.6±0.2°.

Abstract: Disclosed is a preparation method for caspofungin, comprising the steps: (a) a compound as represented in Formula 2 and a strong leaving group 5 are mixed to obtain a compound as represented in Formula 3; (b) the compound as represented in Formula 3 and ethylenediamine are mixed to obtain a compound as represented in Formula 4; and, (c) the compound as represented in Formula 4 is mixed with a hydroxyl protection agent, and then a borane complex is mixed in to obtain a compound as represented in Formula 1.

Abstract: A mobile computing apparatus simulates the performance of a virtual vehicle using the route, driving behavior and loading experience of a baseline vehicle. The baseline vehicle is instrumented and operational data is collected, forming a data set. The apparatus includes simulator logic configured to construct a duty cycle from the data set representative of the operation of the baseline vehicle during travel along the route (e.g., a loading duty cycle). The data set includes route data with distance and vehicle speed information, engine data associated with the engine, and operational element data. The logic defines a virtual vehicle that is the same as the baseline vehicle but that includes a virtual operational element, such as a transmission, that is different than that in the baseline vehicle. The logic determines a performance characteristic, such as fuel economy, of the virtual vehicle using the constructed duty cycle.

Abstract: The present invention relates to a lubiprostone crystal, the method for the preparation thereof, and a pharmaceutical composition or kit comprising the same, as well as the use of said crystal in the preparation of a medicament for the treatment of gastrointestinal tract diseases, especially constipation. The X-ray powder diffraction pattern of said crystal comprises characteristic peaks measured at the following 2? reflection angles: 14.6±0.2°, 17.0±0.2° and 19.6±0.2°. As compared to amorphous lubiprostone, the crystal of the present invention has the advantages of relative high purity, stable properties and easy-for-storage and use.

Abstract: Disclosed are a high purity of caspofungin or salts thereof, and a preparation method thereof, and use thereof. Disclosed are a caspofungin or salts thereof with low solvent residue and hyposaline, and a preparation process comprising: dissolving a crude product of caspofungin or slats thereof into a system of water and acetic acid, them mixing with a first organic solvent ethyl alcohol, subsequently mixing with a second organic solvent ethyl acetate, then being subject to filtration and drying together with water, to obtain caspofungin or salts thereof with high stability, low solvent residue and hyposaline.

Abstract: The method of the preparation of micafungin sodium comprises the step of mixing the weak base and the aqueous solution containing micafungin acid (the structure is illustrated by formula I) or the mixed aqueous solution containing the compound of formula I and organic solvent in order to obtain the sodium salt of micafungin (the structure is illustrated by formula II).

Abstract: The crystalline form A of Bimatoprost of formula I, its preparation method and use are provided. There are characteristic peaks where diffraction angles 2? are 3.2±0.2°, 5.5±0.2°, 11.4±0.2°, 16.7±0.2°, 17.6±0.2°, 19.9±0.2°, 20.8±02° and 22.8±0.2° in the X-ray powder diffraction pattern of the crystalline form A.

Abstract: Disclosed are a caspofungin analog and applications thereof. Said caspofungin analog is a compound having a structure as indicated in Formula (4), or pharmaceutically acceptable slats thereof. R1 can be chosen from hydroxyl, benzyloxy, phenoxy, substituted phenoxy, or substituted benzyloxy. R2, R3, R4, R5 can be chosen from hydrogen, C1-C6 alkyl, C1-C6 alkoxy, hydroxyl, benzyloxyphenyl, substituted benzyloxyphenyl, nitro, fluorine, chlorine, bromine, or iodine. Also disclosed are a preparation method for and applications of said compound.

Abstract: A mobile computing apparatus simulates the performance of a virtual vehicle using the route, driving behavior and loading experience of a baseline vehicle. The baseline vehicle is instrumented and operational data is collected, forming a data set. The apparatus includes simulator logic configured to construct a duty cycle from the data set representative of the operation of the baseline vehicle during travel along the route (e.g., a loading duty cycle). The data set includes route data with distance and vehicle speed information, engine data associated with the engine, and operational element data. The logic defines a virtual vehicle that is the same as the baseline vehicle but that includes a virtual operational element, such as a transmission, that is different than that in the baseline vehicle. The logic determines a performance characteristic, such as fuel economy, of the virtual vehicle using the constructed duty cycle.

Abstract: Disclosed is a preparation method for caspofungin, comprising the steps: (a) a compound as represented in Formula 2 and a strong leaving group 5 are mixed to obtain a compound as represented in Formula 3; (b) the compound as represented in Formula 3 and ethylenediamine are mixed to obtain a compound as represented in Formula 4; and, (c) the compound as represented in Formula 4 is mixed with a hydroxyl protection agent, and then a borane complex is mixed in to obtain a compound as represented in Formula 1.

Abstract: Disclosed are a caspofungin analog, and a preparation method and applications thereof. The caspofungin analog has a structure as represented in Formula 3.

Abstract: Disclosed is a crystal of carboprost tromethamine as represented by Formula (I). The crystal has characteristic peaks in the X-ray diffraction pattern at the following 2? angles: 6.6±0.2°, 9.9±0.2°, 18.5±0.2° and 20.1±0.2°. Furthermore, also disclosed are preparation method and the use of the crystal.

Abstract: A purification method of the compound represented by formula 1 is provided, which includes the following steps: (1) loading crude compound 1 on macroporous adsorbent resin, (2) washing the macroporous adsorbent resin with an aqueous solution, an organic solvent or a mixture solution of organic solvent and water, (3) eluting with an aqueous solution, an organic solvent or a mixture solution of organic solvent and water. The purified compound represented by formula 1 is obtained.

Abstract: The crystalline form A of Bimatoprost of formula I, its preparation method and use are provided. There are characteristic peaks where diffraction angles 2? are 3.2+0.2°, 5.5+0.2°, 11.4+0.2°, 16.7+0.2°, 17.6+0.2°, 19.9+0.2°, 20.8±02° and 22.8+0.2° in the X-ray powder diffraction pattern of the crystalline form A.

Abstract: Disclosed is an exemplary method for optimizing vehicle performance. The method includes determining an optimized drive torque for maximizing vehicle fuel economy and detecting a driver requested drive torque. A determination is made on whether the driver requested drive torque is performance related or safety related. The arbitrated drive torque is set to the optimized drive torque when it is determined that the driver requested drive torque is not performance and safety related. The arbitrated drive torque is set to the driver requested drive torque when it is determined that the driver requested drive torque is either performance or safety related.